%0 Journal Article %A Jay J. Xu %A Jarvis T. Chen %A Thomas R. Belin %A Ronald S. Brookmeyer %A Marc A. Suchard %A Christina M. Ramirez %T Male-Female Disparities in Years of Potential Life Lost Attributable to COVID-19 in the United States: A State-by-State Analysis %D 2021 %R 10.1101/2021.05.02.21256495 %J medRxiv %P 2021.05.02.21256495 %X Males are at higher risk relative to females of severe outcomes following COVID-19 infection. Focusing on COVID-19-attributable mortality in the United States (U.S.), we quantify and contrast years of potential life lost (YPLL) attributable to COVID-19 by sex based on data from the U.S. National Center for Health Statistics as of 31 March 2021, specifically by contrasting male and female percentages of total YPLL with their respective percent population shares and calculating age-adjusted male-to-female YPLL rate ratios both nationally and for each of the 50 states and the District of Columbia. Using YPLL before age 75 to anchor comparisons between males and females and a novel Monte Carlo simulation procedure to perform estimation and uncertainty quantification, our results reveal a near-universal pattern across states of higher COVID-19-attributable YPLL among males compared to females. Furthermore, the disproportionately high COVID-19 mortality burden among males is generally more pronounced when measuring mortality in terms of YPLL compared to age-irrespective death counts, reflecting dual phenomena of males dying from COVID-19 at higher rates and at systematically younger ages relative to females. The U.S. COVID-19 epidemic also offers lessons underscoring the importance of a public health environment that recognizes sex-specific needs as well as different patterns in risk factors, health behaviors, and responses to interventions between men and women. Public health strategies incorporating focused efforts to increase COVID-19 vaccinations among men are particularly urged.Competing Interest StatementT.R.B. has received support from NIH/NCATS grant UL1 TR001881 and NIH/NIMH grant P30 MH058107 in addition to funding outside the scope of this work from the Patient Centered Outcomes Research Institute and the Movember Foundation. M.A.S. has received contracts from Janssen Research & Development, LLC; Private Health Management, Inc.; the United States Department of Veteran Affairs; and the United States Food & Drug Administration and research grants from the National Institutes of Health, all outside the scope of this work. C.M.R. has received a contract from Private Health Management, Inc. outside the scope of this work.Funding StatementThis research received no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referenced in the manuscript are available in the Supplementary Materials.CDCCenters for Disease Control and PreventionCOVID-19Coronavirus Disease 2019D.C.District of ColumbiaMCMonte CarloNCHSNational Center for Health StatisticsRRRate RatioSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2U.S.United StatesYPLLYears of Potential Life Lost %U https://www.medrxiv.org/content/medrxiv/early/2021/05/05/2021.05.02.21256495.full.pdf